Claims for Patent: 6,737,246

Summary for Patent: 6,737,246

Title:	Method for detecting protein inhibitors and ligands of medical value
Abstract:	The invention relates to a method for detecting inhibitors or ligands of binding domains, which comprises using a protein which contains at least one catalytic domain and at least one binding domain, incubating said protein with a marker substrate which binds to the catalytic domain of the protein and is converted, with a substrate which can reversibly bind to the catalytic domain and to the binding domain, and with the inhibitor and determining whether the marker substrate is converted by the protein.
Inventor(s):	Weithmann; Klaus-Ulrich (Hofheim, DE)
Assignee:	Aventis Pharma Deutschland, GmbH (Frankfurt am Main, DE)
Application Number:	09/876,091
Patent Claims:	1. A method to determine whether a test substance inhibits or acts as a ligand of at least one binding domain of a protein, comprising: incubating said test substance with a mixture, wherein said mixture comprises: a) the protein, b) at least one marker substrate, and c) at least one substrate; and determining whether the test substance inhibits or acts as a ligand of at least one binding domain of the protein by comparing the conversion of the marker substrate in the presence of the test substance with the corresponding conversion in control mixtures A and B, wherein the protein contains at least one catalytic domain and at least one binding domain, wherein the marker substrate is converted by said at least one catalytic domain of the protein, wherein the substrate is capable of binding to said at least one catalytic domain and to said at least one binding domain of the protein, wherein the control mixture A comprises the protein and the marker substrate; and the control mixture B comprises the protein, the substrate, and the marker substrate, and wherein the test substance is an inhibitor or ligand of said at least one binding domain of the protein if the conversion of the marker substrate in the presence of the test substance is between the values obtained with control mixtures A and B. 2. The method as claimed in claim 1, wherein the protein is collagenase, the substrate is collagen, and the marker substrate is (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2, 3-diaminopropionyl)-Ala-Arg-NH.sub.2 (SEQ ID NO: 1).

Details for Patent 6,737,246

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2020-06-09